Articles from Alloy Therapeutics

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the successful completion of an antibody discovery collaboration with Mediar Therapeutics. Leveraging Alloy’s ATX-Gx™ human transgenic mouse platform, advanced genetic immunization strategies, and AI/ML-enabled discovery workflows, Alloy delivered a series of differentiated binders against a new challenging target, significantly accelerating Mediar’s development timeline and allowing the company to move high-quality assets into clinical development ahead of schedule.

Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers.

Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines. Through its partnerships, the Genetic Medicines division is dedicated to developing AntiClastic™ nucleic acid medicines to treat diseases at the genetic level.

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies. Under the terms of the collaboration, Alloy will receive an upfront payment from Pfizer and will be eligible for pre-specified preclinical to commercial milestones on products originating from the newly developed platform.

Alloy Therapeutics (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today that it is launching a new market-disrupting licensing structure. Partners can now have the option to use the ATX-Gx™ antibody technology platform with no annual access fee or development milestones. Partners benefit from Alloy as an ever-growing source of pre-competitive, foundational discovery technology.

Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, today announced that it has entered into an institutional licensing agreement with Scripps Research for its ATX-Gx platform for fully human antibody discovery. The non-exclusive license enables all Scripps Research scientists to use the ATX-Gx platform for antibody drug and vaccine discovery workstreams. Scripps Research has been at the forefront of biomedical research since its founding in 1924, and its scientists have played pivotal roles in the development of more than 15 medicines approved by the U.S. Food and Drug Administration.

Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company. The non-exclusive license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms and broad rights to use the Alloy platforms for antibody drug discovery and development under this multi-year collaboration.

Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and more. Alloy’s SAB members have been instrumental in developing Alloy’s technical roadmap as the company has developed cutting edge technologies and services across antibodies, bispecifics, TCRs and TCR mimics, genetic medicines, cell therapies, peptides and drug delivery technologies.

Alloy Therapeutics, a biotechnology ecosystem company, announced expanded leadership to strengthen its portfolio of drug discovery capabilities and technologies for the global scientific community. Michael Schmidt, PhD has joined the company as its Chief Scientific Officer (CSO), where he will oversee technical innovation and ensure high scientific quality for Alloy’s broad portfolio of platforms, services, and venture studio company creation. Alloy has promoted Martin Leach, PhD, MBA to Chief Operating Officer (COO), from his previous position of Alloy Senior Vice President of Global Informatics and COO of its Daedamab research facility.

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense. Alloy has exclusively licensed IP underlying the AntiClastic ASO platform from Sudhir Agrawal’s Arnay Sciences LLC.

Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies.

Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members of its team, joining as Senior Vice President of Antibody Discovery Services and Senior Vice President of Therapeutic Discovery Strategies, respectively. In conjunction with the addition of these new team members, Alloy is also expanding its Antibody Discovery Services, offering partners the choice of two initial core discovery approaches to meet their specific research and development needs, with the option to invest in value-add service modules to further candidates toward clinical development. These updates underscore Alloy’s ongoing commitment to reinvest 100% of its revenue back into innovation and access to innovation.

Alloy Therapeutics, a biotechnology ecosystem company, announced its 2023 roadmap of new discovery technologies and services across a range of biologic modalities. Alloy will support its community of 140+ partners with deepened capabilities in its core antibodies offering, as well as substantial expansion into new modalities such as genetic medicines, leveraging an existing partnership announced with Dr. Sudhir Agrawal, a pioneer of gapmer antisense oligonucleotide (ASO) technology.

Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the advancement of Normunity’s immune normalizers, antibody therapies designed to target novel mechanisms that free the body’s normal immunity to fight cancer, which are conceived through a unique biotech-academic collaboration with a renowned immuno-oncology university research lab.

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership models designed to fuel innovation.

Alloy Therapeutics, a biotechnology ecosystem company, welcomes Trier Bryant as President of 82VS, Alloy’s affiliated venture studio. Trier is a strategic executive leader with distinctive tech, Wall Street, and military experience spanning 15 years, and brings a people-first approach to leading and scaling the 82VS team and ecosystem of startup companies.

Alloy Therapeutics, a biotechnology ecosystem company, announced a collaboration and licensing agreement with Sudhir Agrawal’s Arnay Sciences to advance new RNA-based drug discovery platforms and novel chemistries spanning the fields of antisense therapeutics to immunomodulating therapeutics. The collaboration demonstrates Alloy’s dedication to expanding its ecosystem offerings into genetic medicines. In collaboration with Dr. Agrawal, Alloy will advance the core technology platforms developed by Arnay into a multitude of new applications, which will initially be available to new companies formed within its Venture Studio, 82VS. Dr. Agrawal will also serve as the Scientific Advisory Board chair of Alloy's genetic medicine platform technologies.

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning (ML) capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire additional computational scientists and developers as it grows with the Alloy network.

Alloy Therapeutics (“Alloy”) and Pyxis Oncology ("Pyxis") today announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases. Kyma Therapeutics will advance programs directed to immune-modulating targets identified by Pyxis. Alloy Discovery Services will generate therapeutic candidates using Alloy’s broad suite of human antibody discovery technologies, including the ATX-Gx™ mouse platform while Pyxis will develop assays and perform ex-vivo and in-vivo studies on the therapeutic candidates.